A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer

Melissa A. Geller; Joseph J. Ivy; Rahel Ghebre; Levi S. Downs; Patricia L. Judson; Linda F. Carson; Amy L. Jonson; Kathryn Dusenbery; Rachel Isaksson Vogel; Matthew P. Boente; Peter A. Argenta

doi:10.1016/j.ygyno.2010.12.338

A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer

Melissa A. Geller, Joseph J. Ivy, Rahel Ghebre, Levi S. Downs, Patricia L. Judson, Linda F. Carson, Amy L. Jonson, Kathryn Dusenbery, Rachel Isaksson Vogel, Matthew P. Boente, Peter A. Argenta

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

Objective: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m²) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21-81 years). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%). Conclusions: "Sandwiching" radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.

Original language	English (US)
Pages (from-to)	112-117
Number of pages	6
Journal	Gynecologic oncology
Volume	121
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2010.12.338
State	Published - Apr 2011

Bibliographical note

Funding Information:
This study was supported financially by Sanofi-Aventis and in part by NIH P30 CA77598 utilizing the Masonic Cancer Center, University of Minnesota Biostatistics and Bioinformatics Core. We would like to thank Justin Chura, MD for his assistance in data collection as well as Elaine Bell RN, BSN, OCN Oncology Research Manager for her excellence in study coordination and patient care during this trial.

Keywords

Advanced stage
Chemotherapy
Endometrial cancer
Radiation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.ygyno.2010.12.338

OpenUrl availability

Full text

Cite this

Geller, M. A., Ivy, J. J., Ghebre, R., Downs, L. S., Judson, P. L., Carson, L. F., Jonson, A. L., Dusenbery, K., Vogel, R. I., Boente, M. P., & Argenta, P. A. (2011). A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecologic oncology, 121(1), 112-117. https://doi.org/10.1016/j.ygyno.2010.12.338

Geller, MA, Ivy, JJ, Ghebre, R, Downs, LS, Judson, PL, Carson, LF, Jonson, AL, Dusenbery, K, Vogel, RI, Boente, MP & Argenta, PA 2011, 'A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer', Gynecologic oncology, vol. 121, no. 1, pp. 112-117. https://doi.org/10.1016/j.ygyno.2010.12.338

@article{d229fafe711844a9af03a7fc43129d49,

title = "A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a {"}Sandwich{"} method for stage III, IV, and recurrent endometrial cancer",

abstract = "Objective: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m2) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21-81 years). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%). Conclusions: {"}Sandwiching{"} radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.",

keywords = "Advanced stage, Chemotherapy, Endometrial cancer, Radiation",

author = "Geller, {Melissa A.} and Ivy, {Joseph J.} and Rahel Ghebre and Downs, {Levi S.} and Judson, {Patricia L.} and Carson, {Linda F.} and Jonson, {Amy L.} and Kathryn Dusenbery and Vogel, {Rachel Isaksson} and Boente, {Matthew P.} and Argenta, {Peter A.}",

note = "Funding Information: This study was supported financially by Sanofi-Aventis and in part by NIH P30 CA77598 utilizing the Masonic Cancer Center, University of Minnesota Biostatistics and Bioinformatics Core. We would like to thank Justin Chura, MD for his assistance in data collection as well as Elaine Bell RN, BSN, OCN Oncology Research Manager for her excellence in study coordination and patient care during this trial.",

year = "2011",

month = apr,

doi = "10.1016/j.ygyno.2010.12.338",

language = "English (US)",

volume = "121",

pages = "112--117",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer

AU - Geller, Melissa A.

AU - Ivy, Joseph J.

AU - Ghebre, Rahel

AU - Downs, Levi S.

AU - Judson, Patricia L.

AU - Carson, Linda F.

AU - Jonson, Amy L.

AU - Dusenbery, Kathryn

AU - Vogel, Rachel Isaksson

AU - Boente, Matthew P.

AU - Argenta, Peter A.

N1 - Funding Information: This study was supported financially by Sanofi-Aventis and in part by NIH P30 CA77598 utilizing the Masonic Cancer Center, University of Minnesota Biostatistics and Bioinformatics Core. We would like to thank Justin Chura, MD for his assistance in data collection as well as Elaine Bell RN, BSN, OCN Oncology Research Manager for her excellence in study coordination and patient care during this trial.

PY - 2011/4

Y1 - 2011/4

N2 - Objective: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m2) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21-81 years). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%). Conclusions: "Sandwiching" radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.

AB - Objective: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m2) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21-81 years). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%). Conclusions: "Sandwiching" radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.

KW - Advanced stage

KW - Chemotherapy

KW - Endometrial cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=79952817755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952817755&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.12.338

DO - 10.1016/j.ygyno.2010.12.338

M3 - Article

C2 - 21239048

AN - SCOPUS:79952817755

SN - 0090-8258

VL - 121

SP - 112

EP - 117

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 1

ER -

A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this